These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 16724312)
1. Blood safety and the choice of anti-hemophilic factor concentrate. Valentino LA; Oza VM Pediatr Blood Cancer; 2006 Sep; 47(3):245-54. PubMed ID: 16724312 [TBL] [Abstract][Full Text] [Related]
2. Blood safety and the choice of anti-hemophilic factor concentrate. Janco RL Pediatr Blood Cancer; 2007 Jan; 48(1):117. PubMed ID: 17063470 [No Abstract] [Full Text] [Related]
3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic properties and safety of recombinant factor VIII and factor IX. Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K; Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223 [TBL] [Abstract][Full Text] [Related]
5. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia]. Pollmann H Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261 [TBL] [Abstract][Full Text] [Related]
6. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III. McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666 [TBL] [Abstract][Full Text] [Related]
7. [Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations]. Sutor AH Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):595-9. PubMed ID: 1714865 [TBL] [Abstract][Full Text] [Related]
8. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914 [TBL] [Abstract][Full Text] [Related]
9. Pennsylvania state-wide hemophilia program: summary of immediate reactions with the use of factor VIII and factor IX concentrate. Prager D; Djerassi I; Eyster ME; Gill FM; Kajani NK; Lewis JH; Lusch C; Rice S; Shapiro SS Blood; 1979 May; 53(5):1012-3. PubMed ID: 435636 [No Abstract] [Full Text] [Related]
10. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730 [TBL] [Abstract][Full Text] [Related]
11. Concentrate safety and efficacy. Kasper CK Haemophilia; 2002 May; 8(3):161-5. PubMed ID: 12010404 [TBL] [Abstract][Full Text] [Related]
12. The safety of pharmacologic options for the treatment of persons with hemophilia. Franchini M; Mannucci PM Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551 [TBL] [Abstract][Full Text] [Related]
14. Why prescribe highly purified factor VIII and IX concentrates? Berntorp E Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765 [TBL] [Abstract][Full Text] [Related]
15. Coagulation products and their uses. Shord SS; Lindley CM Am J Health Syst Pharm; 2000 Aug; 57(15):1403-17; quiz 1418-20. PubMed ID: 10938981 [TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of 4 Chinese hemophiliacs with human immunodeficiency virus infection]. Tang DJ; Xu YH; Dai D Zhonghua Nei Ke Za Zhi; 1989 Aug; 28(8):466-8, 509. PubMed ID: 2513171 [TBL] [Abstract][Full Text] [Related]
17. Hemophiliacs with inhibitors: therapeutic options. Roberts HR N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992 [No Abstract] [Full Text] [Related]